Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2018-12-06 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2018
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30 November 2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other agreements related to shares. The content is focused on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital changes and securities movements for a specific month. The document is lengthy (15,000 characters) and contains detailed tables of share movements, which is typical for a regulatory filing related to share capital changes. It does not fit the definitions of Annual Report, Earnings Release, Management Reports, or other financial reports. It is not a report publication announcement since it contains substantive data. Therefore, the best fitting category is Share Issue/Capital Change (SHA).
2018-12-06 English
VOLUNTARY ANNOUNCEMENT UNI-E4 INJECTION PHASE III CLINICAL TRIAL APPLICATION ACCEPTED BY CENTER FOR DRUG EVALUATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Uni-Bio Science Group Limited regarding the acceptance of their Phase III clinical trial application for a drug by the Center for Drug Evaluation, China Food and Drug Administration. It is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. The document is relatively short (3566 characters) and serves as a public disclosure of a significant event rather than a detailed report or presentation. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-11-26 English
DISCLOSEABLE AND CONNECTED TRANSACTIONS - TRANSACTION ARRANGEMENTS
M&A Activity Classification · 95% confidence The document is an announcement from a company listed on the Hong Kong Stock Exchange regarding discloseable and connected transactions involving the sale of subsidiaries and property rights. It details transaction arrangements, parties involved, consideration amounts, conditions precedent, and the need for shareholder approval at an Extraordinary General Meeting (EGM). The content focuses on transaction agreements and related corporate actions rather than financial results, management changes, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document is a formal announcement of significant corporate transactions requiring shareholder approval, fitting the category of M&A Activity announcements rather than the actual merger/acquisition filings or proxy statements. Therefore, the appropriate classification is 'TAR' (M&A Activity). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-11-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2018
Major Shareholding Notification Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 October 2018, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related instruments. The content is focused on changes in share capital and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements as required by the exchange. The document is lengthy (15,000 characters) and contains detailed tables of share capital changes, but it is not an annual or interim financial report, nor an earnings release or management discussion. It is a regulatory compliance filing specific to share capital movements. Therefore, the most appropriate classification is Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership or share capital movements for listed companies.
2018-11-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2018
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report on movements in securities for Uni-Bio Science Group Limited, submitted to the Hong Kong Exchanges and Clearing Limited. It includes detailed tables on movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other agreements or arrangements to issue shares. The document is dated for the month ended 30 September 2018 and contains no financial statements or earnings data but focuses on share capital changes and securities movements. This type of document is a regulatory filing specific to share capital movements and securities disclosures required by the exchange, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the report itself of monthly securities movements. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like Share Issue/Capital Change (SHA) because it covers a broad range of securities movements and is a standard regulatory submission to the exchange.
2018-10-02 English
NOTIFICATION LETTER AND REQUEST FORM
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 21 September 2018 from Uni-Bio Science Group Limited informing shareholders that the 2018 interim report for the six months ended 30 June 2018 has been published on the company's website. It includes instructions on how shareholders can request a printed copy of the interim report and future corporate communications. The document does not contain the interim report itself or any financial data, but rather serves as a notice of publication and availability of the report. The document length is 4673 characters, which is relatively short and consistent with a notification letter rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA) rather than an Interim Report (IR).
2018-09-21 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.